An Open-Label Trial of Adjunctive Oxcarbazepine for Bipolar Disorder

“…There is currently no evidence that tolerability is improved by the extended release formulation, and carbamazepine remains a second‐line choice. Additional open‐label and chart review data add to the support for efficacy of adjunctive oxcarbazepine (20, 21).…”

mentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The dosage ranged from 919 to 1200 mg/day, and time of exposure to OXC ranged from 8 weeks to 16 months. [15][16][17]23]. There are two retrospective chart reviews that reported the efficacy of OXC in depressed patients with bipolar, schizoaffective and unipolar disorders [19,20].…”

Section: Antidepressant Effects Of Oxcarbazepinementioning

confidence: 98%

“…12 1 bipolar II, 5 NOS 28.0 ± 7.6 weeks Retrospective naturalistic study Adjunct OXC showed mild/marked improvement [24] Adjunct to risperidone Improved scores on CGI, PANSS, YMRS and HAM-D scales [21] MalekAhmadi et al 24 weeks [2,7,[15][16][17]. One open-label trial, ABA design, studying the efficacy of OXC as monotherapy for acute manic, was performed in 12 bipolar I patients.…”

Section: Weeksmentioning

confidence: 99%

See 1 more Smart Citation

Oxcarbazepine in the treatment of bipolar and schizoaffective disorders

Popova¹,

Leighton²,

Bernabarre³

et al. 2007

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Oxcarbazepine is an antiepileptic drug that has been approved by the US FDA and is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children aged over 4 years. The aim of this report is to investigate the results of clinical trials in order to ascertain the efficacy and safety of oxcarbazepine for use in bipolar disorder and schizoaffective disorder. Oxcarbazepine is a keto-congener of carbamazepine with fewer side effects and drug interactions. Orally administrated oxcarbazepine is rapidly and completely absorbed and has a half-life of 9 h. Currently, there is a lack of controlled clinical trials studying the use of oxcarbazepine. In light of controlled and open-label prospective studies, it may be useful for manic symptoms in the treatment of bipolar and schizoaffective patients. Case reports, retrospective and prospective studies suggest that oxcarbazepine might have prophylactic efficacy and long-term benefit for these patients. In addition, owing to its lower propensity for drug interactions and side effects, it may be useful in the treatment of refractory patients with bipolar and schizoaffective disorder. However, most of the trials have relevant methodological shortcomings. The side-effect profile of oxcarbazepine is similar to carbamazepine, but the severity of these effects appears to be slightly less. The symptoms that are most frequently associated with the use of oxcarbazepine are asthenia, headache, dizziness, somnolence, nausea, diplopia and skin rash. Isolated cases of hyponatremic coma have been reported, thus electrolyte abnormalities should be closely monitored. Oxcarbazepine is now a generic drug, but the metabolite licarbazepine and other related compounds, such as eslicarbazepine, are currently being studied under controlled conditions and might become useful therapies for bipolar and schizoaffective disorder in the future.

show abstract